Sysmex France
Menu

Patient stratification and prognostic scores – the value of routine diagnostic parameters in supporting COVID-19 disease management

Identification of COVID-19-positive patients upon hospital admission usually relies on RT-PCR tests, however, clinicians can utilise diagnostic information to make decisions during the first examination of a patient as well. If risk factors are already known, this can be combined with laboratory tests to provide an informed initial evaluation.

The importance of risk stratification

Assessing patients’ risk factors and categories can support in planning, developing and implementing a more personalised care plan. By providing a risk status for patients, the right level of care can be identified for distinct groups of patients with similar care needs. This can have the effect of efficient, targeted resource planning and improving overall health outcomes.*

The value of parameters and prognostic scores

A prognostic score to indicate early the need for ICU care and thus support patient management has been developed by clinical scientists and based on parameters from Sysmex XN-Series haematology analyser. Parameters reflecting patients’ immune cell activation such as antibody synthesising lymphocytes (AS-LYMP) are used, thus the score characterises the strength of immune response towards the infection. Based on parameter values measured within the first three days after presentation, the score is potentially able to predict the clinical severity of the infection within a two-week timeframe. Thus, the score may have the potential to differentiate between patients who will recover without ventilation or deteriorate during this timeframe, or those who will need intensive care or have a fatal outcome. All parameters are generated from a Sysmex XN complete blood count (CBC) with differential. Since Sysmex haematology analysers are widely available in the European market, this makes this common and baseline test accessible to many people.**

What are early indicators for a severe course of SARS-CoV-2 infection?

The infection course among patients is highly variable, but several laboratory parameters have been associated with severe and/or critical disease. An initial evaluation can be performed from the results of a CBC. In patients who test positive for COVID-19, white blood cells along with the main subpopulations (neutrophils, lymphocytes and monocytes) are reduced, whereas haematological parameters that explore the activation status of cell populations, such as high-fluorescent lymphocytes (HFL) are elevated.

Patients with severe disease showed a significantly lower platelet count, a shorter activated partial thromboplastin time (APTT), but higher D-dimer levels, higher fibrin degradation product (FDP) levels, higher fibrinogen levels and a prolonged prothrombin time. In addition, lymphopenia, neutrophilia, increased white blood cell and neutrophil counts with concurrent lymphocytopenia, and thrombocytopenia may be prognosticators upon hospital admission. However, it is still challenging for a single parameter to assess disease severity with high accuracy due to strong individual variation and rapid change over time.

Visit our COVID-19 site, which provides detailed information on all parameters where Sysmex products are able to give insights on disease progression and management.

 

* National Association of Community Health Centers. (2019) https://www.nachc.org/wp-content/uploads/2019/03/Risk-Stratification-Action-Guide-Mar-2019.pdf

** These statements are based on a multicentre feasibility study published in eLife Sciences Publiscations, Ltd.

All other references can be found on the detailed webpage:

 

Explore more

Back to overview
Copyright © Sysmex Europe GmbH. All rights reserved.
Information

Nous informons les visiteurs que ce site Internet est, uniquement, à destination des professionnels de santé (*)
Merci de confirmer que vous êtes un professionnel de santé (*)

(*) Un professionnel de santé est défini comme toute personne habilitée à prescrire, dispenser ou utiliser des DMDIV (Dispositifs Médicaux de Diagnostic In Vitro) dans l’exercice de son art.

Excusez-nous.

Cette page est réservée aux professionnels. Ils ne sont pas autorisés.

Personnalisez vos paramètres

Nous utilisons des cookies pour vous permettre une utilisation optimale de notre site web et pour améliorer notre communication avec vous. Nous tenons compte de vos choix et nous n’utilisons que les données pour lesquelles vous nous donnez votre consentement.

* Peut conduire à des restrictions dans les contenus et l’expérience d’utilisateur
Détails sur les cookies
Cookies strictement nécessaires
Ces cookies contribuent à l’exploitation de notre site web en autorisant des fonctions de base, telles que la navigation sur le site et l’accès à des zones sécurisées de notre site web. Notre site web ne peut pas fonctionner correctement sans ces cookies.
Cookies de statistiques
Ces cookies nous aident à comprendre comment des visiteurs interagissent avec notre site web, en récoltant des informations de façon anonyme. Ces informations nous permettent d’améliorer constamment notre offre.
Cookies marketing
Ils sont utilisés pour tracer des visiteurs sur des sites web. Ils ont pour objet de montrer des annonces pertinentes et attractives à chaque utilisateur et donc précieuses pour les éditeurs et les annonceurs tiers.